Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study
Objective To investigate limiting factors of American College of Rheumatology (ACR)/EULAR Boolean remission in rheumatoid arthritis (RA), and compare patients who fulfil the criteria to patients who only partly fulfil the criteria, with respect to imaging inflammation and biologic disease modifying...
Published in: | RMD Open |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
BMJ Group
2022
|
Subjects: | |
Online Access: | http://hdl.handle.net/10852/101310 https://doi.org/10.1136/rmdopen-2021-002013 |
id |
ftoslouniv:oai:www.duo.uio.no:10852/101310 |
---|---|
record_format |
openpolar |
spelling |
ftoslouniv:oai:www.duo.uio.no:10852/101310 2023-05-15T15:13:52+02:00 Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study ENEngelskEnglishInflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study Sundlisæter, Nina Beate Paulshus Sundin, Ulf Gunnar Aga, Anna-Birgitte Sexton, Joseph Hammer, Hilde Berner Uhlig, Till Kvien, Tore Kristian Haavardsholm, Espen A. Lillegraven, Siri 2022-04-28T11:05:37Z http://hdl.handle.net/10852/101310 https://doi.org/10.1136/rmdopen-2021-002013 EN eng BMJ Group Sundlisæter, Nina Beate Paulshus Sundin, Ulf Gunnar Aga, Anna-Birgitte Sexton, Joseph Hammer, Hilde Berner Uhlig, Till Kvien, Tore Kristian Haavardsholm, Espen A. Lillegraven, Siri . Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study. RMD Open. 2022, 8(1) http://hdl.handle.net/10852/101310 2019746 info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=RMD Open&rft.volume=8&rft.spage=&rft.date=2022 RMD Open 8 1 0 https://doi.org/10.1136/rmdopen-2021-002013 Attribution-NonCommercial 4.0 International https://creativecommons.org/licenses/by-nc/4.0/ 2056-5933 Journal article Tidsskriftartikkel Peer reviewed PublishedVersion 2022 ftoslouniv https://doi.org/10.1136/rmdopen-2021-002013 2023-03-15T23:36:44Z Objective To investigate limiting factors of American College of Rheumatology (ACR)/EULAR Boolean remission in rheumatoid arthritis (RA), and compare patients who fulfil the criteria to patients who only partly fulfil the criteria, with respect to imaging inflammation and biologic disease modifying anti-rheumatic drug (DMARD) usage. Methods Patients with DMARD-naïve RA were treated according to current recommendations in the the ARCTIC trial (Aiming for Remission in rheumatoid arthritis: a randomised trial examining the benefit of ultrasound in a Clinical TIght Control regimen). Limiting factors of reaching ACR/EULAR Boolean remission at 2 years were assessed. Imaging inflammation (ultrasound and MRI) in patients in remission was compared with patients failing to fulfil different components of the criteria. The OR of biologic therapy was calculated using logistic regression. Results Of 203 patients, 112 (55%) reached ACR/EULAR Boolean remission; 49 (24%) fulfilled three of four criteria. The main limiting factors were patient global assessment (PGA) (59%) and tender joints (22%). Imaging inflammation was not significantly different for patients in remission and patients not fulfilling the criteria due to elevated PGA and/or tender joints, but higher odds of using biologics (OR 3.63, 95% CI 1.73 to 7.61) were observed. Conclusions PGA and tender joints were the factors most often limiting achievement of ACR/EULAR Boolean remission. The level of imaging inflammation was not elevated in these patients compared with patients in remission, but the odds of using biologic DMARDs were higher. Article in Journal/Newspaper Arctic Universitet i Oslo: Digitale utgivelser ved UiO (DUO) Arctic RMD Open 8 1 e002013 |
institution |
Open Polar |
collection |
Universitet i Oslo: Digitale utgivelser ved UiO (DUO) |
op_collection_id |
ftoslouniv |
language |
English |
description |
Objective To investigate limiting factors of American College of Rheumatology (ACR)/EULAR Boolean remission in rheumatoid arthritis (RA), and compare patients who fulfil the criteria to patients who only partly fulfil the criteria, with respect to imaging inflammation and biologic disease modifying anti-rheumatic drug (DMARD) usage. Methods Patients with DMARD-naïve RA were treated according to current recommendations in the the ARCTIC trial (Aiming for Remission in rheumatoid arthritis: a randomised trial examining the benefit of ultrasound in a Clinical TIght Control regimen). Limiting factors of reaching ACR/EULAR Boolean remission at 2 years were assessed. Imaging inflammation (ultrasound and MRI) in patients in remission was compared with patients failing to fulfil different components of the criteria. The OR of biologic therapy was calculated using logistic regression. Results Of 203 patients, 112 (55%) reached ACR/EULAR Boolean remission; 49 (24%) fulfilled three of four criteria. The main limiting factors were patient global assessment (PGA) (59%) and tender joints (22%). Imaging inflammation was not significantly different for patients in remission and patients not fulfilling the criteria due to elevated PGA and/or tender joints, but higher odds of using biologics (OR 3.63, 95% CI 1.73 to 7.61) were observed. Conclusions PGA and tender joints were the factors most often limiting achievement of ACR/EULAR Boolean remission. The level of imaging inflammation was not elevated in these patients compared with patients in remission, but the odds of using biologic DMARDs were higher. |
format |
Article in Journal/Newspaper |
author |
Sundlisæter, Nina Beate Paulshus Sundin, Ulf Gunnar Aga, Anna-Birgitte Sexton, Joseph Hammer, Hilde Berner Uhlig, Till Kvien, Tore Kristian Haavardsholm, Espen A. Lillegraven, Siri |
spellingShingle |
Sundlisæter, Nina Beate Paulshus Sundin, Ulf Gunnar Aga, Anna-Birgitte Sexton, Joseph Hammer, Hilde Berner Uhlig, Till Kvien, Tore Kristian Haavardsholm, Espen A. Lillegraven, Siri Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study |
author_facet |
Sundlisæter, Nina Beate Paulshus Sundin, Ulf Gunnar Aga, Anna-Birgitte Sexton, Joseph Hammer, Hilde Berner Uhlig, Till Kvien, Tore Kristian Haavardsholm, Espen A. Lillegraven, Siri |
author_sort |
Sundlisæter, Nina Beate Paulshus |
title |
Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study |
title_short |
Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study |
title_full |
Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study |
title_fullStr |
Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study |
title_full_unstemmed |
Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study |
title_sort |
inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving acr/eular boolean remission in a treat-to-target study |
publisher |
BMJ Group |
publishDate |
2022 |
url |
http://hdl.handle.net/10852/101310 https://doi.org/10.1136/rmdopen-2021-002013 |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
2056-5933 |
op_relation |
Sundlisæter, Nina Beate Paulshus Sundin, Ulf Gunnar Aga, Anna-Birgitte Sexton, Joseph Hammer, Hilde Berner Uhlig, Till Kvien, Tore Kristian Haavardsholm, Espen A. Lillegraven, Siri . Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study. RMD Open. 2022, 8(1) http://hdl.handle.net/10852/101310 2019746 info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=RMD Open&rft.volume=8&rft.spage=&rft.date=2022 RMD Open 8 1 0 https://doi.org/10.1136/rmdopen-2021-002013 |
op_rights |
Attribution-NonCommercial 4.0 International https://creativecommons.org/licenses/by-nc/4.0/ |
op_doi |
https://doi.org/10.1136/rmdopen-2021-002013 |
container_title |
RMD Open |
container_volume |
8 |
container_issue |
1 |
container_start_page |
e002013 |
_version_ |
1766344389821464576 |